Released : January 24, 2020 16:31 RNS Number : 9167A MaxCyte, Inc. 24 January 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Gaithersburg, Maryland - 24 January 2020 : MaxCyte (LSE: MXCT, MXCS), the global clinical-stage cell-based therapies and life sciences
Released : January 22, 2020 17:15 RNS Number : 6475A MaxCyte, Inc. 22 January 2020 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Released : January 22, 2020 17:11 RNS Number : 6469A MaxCyte, Inc. 22 January 2020 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Released : January 22, 2020 17:08 RNS Number : 6465A MaxCyte, Inc. 22 January 2020 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Released : January 20, 2020 07:00 RNS Number : 2421A MaxCyte, Inc. 20 January 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update · Revenue exceeds market expectations · Five new gene-editing cell therapy deals signed in 2019; eight clinical and commercial cell
Released : December 19, 2019 07:00 RNS Number : 4058X MaxCyte, Inc. 19 December 2019 MaxCyte Appoints New Executive Vice President, Business Development for CARMA™ Cellular Therapies and Trial Update - Shruti Abbato will lead development of new partnerships for the Company's
Released : December 16, 2019 17:25 RNS Number : 0553X MaxCyte, Inc. 16 December 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Director/PCA transaction initial notification Gaithersburg, Maryland - 16 December 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life
Released : December 04, 2019 07:00 RNS Number : 5710V MaxCyte, Inc. 04 December 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ's Adoptive Cell Therapy Programs
Released : November 21, 2019 07:00 RNS Number : 1251U MaxCyte, Inc. 21 November 2019 Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer - Clinical and commercial agreement using MaxCyte's
Released : November 14, 2019 07:00 RNS Number : 3429T MaxCyte, Inc. 14 November 2019 MaxCyte to Present at 2019 Jefferies London Healthcare Conference Gaithersburg, Maryland - 14 November 2019 - MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company,
